JPS57206622A - Blood substitute - Google Patents

Blood substitute

Info

Publication number
JPS57206622A
JPS57206622A JP56089315A JP8931581A JPS57206622A JP S57206622 A JPS57206622 A JP S57206622A JP 56089315 A JP56089315 A JP 56089315A JP 8931581 A JP8931581 A JP 8931581A JP S57206622 A JPS57206622 A JP S57206622A
Authority
JP
Japan
Prior art keywords
hemoglobin
joined
give
blood substitute
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP56089315A
Other languages
English (en)
Japanese (ja)
Other versions
JPH026337B2 (enExample
Inventor
Yuji Iwashita
Katsumi Ajisaka
Takaharu Iwasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP56089315A priority Critical patent/JPS57206622A/ja
Priority to EP82302826A priority patent/EP0067029B1/en
Priority to DE8282302826T priority patent/DE3270842D1/de
Priority to US06/384,606 priority patent/US4412989A/en
Publication of JPS57206622A publication Critical patent/JPS57206622A/ja
Publication of JPH026337B2 publication Critical patent/JPH026337B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP56089315A 1981-06-10 1981-06-10 Blood substitute Granted JPS57206622A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP56089315A JPS57206622A (en) 1981-06-10 1981-06-10 Blood substitute
EP82302826A EP0067029B1 (en) 1981-06-10 1982-06-02 Oxygen carrier
DE8282302826T DE3270842D1 (en) 1981-06-10 1982-06-02 Oxygen carrier
US06/384,606 US4412989A (en) 1981-06-10 1982-06-03 Oxygen carrier

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56089315A JPS57206622A (en) 1981-06-10 1981-06-10 Blood substitute

Publications (2)

Publication Number Publication Date
JPS57206622A true JPS57206622A (en) 1982-12-18
JPH026337B2 JPH026337B2 (enExample) 1990-02-08

Family

ID=13967228

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56089315A Granted JPS57206622A (en) 1981-06-10 1981-06-10 Blood substitute

Country Status (4)

Country Link
US (1) US4412989A (enExample)
EP (1) EP0067029B1 (enExample)
JP (1) JPS57206622A (enExample)
DE (1) DE3270842D1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5989629A (ja) * 1982-11-15 1984-05-23 Ajinomoto Co Inc 代用血液
JPS6153223A (ja) * 1984-08-22 1986-03-17 Ajinomoto Co Inc ヘモグロビン−ポリアルキレングリコ−ル結合体の製造方法
JPS6289630A (ja) * 1985-06-19 1987-04-24 Ajinomoto Co Inc ヘモグロビン―ポリオキシアルキレン結合体
JPH01500524A (ja) * 1986-07-02 1989-02-23 パスツール・メリュー・セルム・エ・バクサン ヘモグロビン高分子複合体、その調製方法及びその利用分野
JP2005515225A (ja) * 2002-01-11 2005-05-26 サンガート， インコーポレイテッド 高酸素親和性改変ヘモグロビンを含む、酸素輸送のための方法および組成物
US7235639B2 (en) 2003-04-23 2007-06-26 Ezio Panzeri Hemoglobin conjugates

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2551660B1 (fr) * 1983-09-13 1986-11-14 Centre Nat Rech Scient Hemoglobine modifiee chimiquement, sa preparation, solutions aqueuses en contenant et leur utilisation
GB8328917D0 (en) * 1983-10-28 1983-11-30 Fisons Plc Blood substitute
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5955581A (en) * 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5753616A (en) * 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5650388A (en) * 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5386014A (en) * 1989-11-22 1995-01-31 Enzon, Inc. Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute
US5312808A (en) * 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US6172039B1 (en) 1990-04-16 2001-01-09 Apex Bioscience, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
US5248766A (en) * 1990-08-17 1993-09-28 Baxter International Inc. Oxirane-modified hemoglobin based composition
US5334705A (en) * 1991-08-15 1994-08-02 Duke University Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
DE69226197T2 (de) * 1991-11-08 1999-02-11 Somatogen, Inc., Boulder Hämoglobine als arzneimittelabgabesystem
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5264555A (en) * 1992-07-14 1993-11-23 Enzon, Inc. Process for hemoglobin extraction and purification
US5387672A (en) * 1993-03-02 1995-02-07 The University Of Maryland At Baltimore Hemoglobin intramolecularly cross-linked withlong chain divalent reagents
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5612310A (en) * 1993-05-24 1997-03-18 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5578564A (en) * 1993-07-23 1996-11-26 Somatogen, Inc. Nickel-free hemoglobin and methods for producing such hemoglobin
US5840851A (en) * 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5807831A (en) * 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5767089A (en) * 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) * 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) * 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5840701A (en) * 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5585484A (en) * 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6833408B2 (en) 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
PT1704878E (pt) * 1995-12-18 2013-07-17 Angiodevice Internat Gmbh Composições de polímeros reticulados e métodos para a sua utilização
US7883693B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
JP3092531B2 (ja) * 1996-11-05 2000-09-25 日本油脂株式会社 コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
JP4583510B2 (ja) * 1997-02-28 2010-11-17 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 無細胞系による酸素輸送の最適化のための方法と組成物
US5814601A (en) * 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
KR20010085742A (ko) 1998-08-28 2001-09-07 추후제출 정밀한 길이의 폴리아미드 사슬, 그 제조방법 및 단백질결합체의 제조방법
JP2000230000A (ja) * 1999-02-08 2000-08-22 Hokkaido Univ 一酸化窒素代謝物−ポリオキシアルキレン−ヘモグロビン結合体
DE10031744A1 (de) 2000-06-29 2002-01-17 Sanguibio Tech Ag Mit Blutplasma verträgliche, vernetzte und mit Polyalkylenoxiden konjugierte Säugetierhämoglobine als künstliche medizinische Sauerstoffträger, ihre Herstellung und ihre Verwendung
DE10031740A1 (de) 2000-06-29 2002-02-14 Sanguibio Tech Ag Künstliche Sauerstoffträger aus vernetztem modifizierten Human- oder Schweinehämoglobin mit verbesserten Eigenschaften, Verfahren zu ihrer technisch einfachen Herstellung aus gereinigtem Material in hohen Ausbeuten, sowie deren Verwendung
JP2006500115A (ja) 2000-11-16 2006-01-05 マイクロスフエリツクス・エル・エル・シー 密封小線源治療用の可撓性および／または弾性シードまたはストランド
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
AU2002320628A1 (en) * 2001-07-19 2003-03-03 Albert Einstein College Of Medecine Of Yeshiva University Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy akylene glycols
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7439043B2 (en) * 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7297511B2 (en) * 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
ES2466024T3 (es) * 2001-10-10 2014-06-09 Ratiopharm Gmbh Remodelación y glicoconjugación de factor de crecimiento de fibroblastos (FGF)
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7473680B2 (en) * 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10226990A1 (de) * 2002-06-18 2004-03-18 Sanguibiotech Ag Topisch applizierbare Mikro-Emulsionen mit binärer Phasen- und Wirkstoffdifferenzierbarkeit, deren Herstellung und deren Verwendung, insbesondere zur Versorgung der Haut mit bioverfügbarem Sauerstoff
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
JP3912206B2 (ja) * 2002-07-05 2007-05-09 株式会社日立製作所 筒内直接燃料噴射装置用燃料ポンプ
KR20040005397A (ko) * 2002-07-10 2004-01-16 이대평 게르마늄 치환기를 가진 포르피린 유도체의 제조방법
BR0314107A (pt) * 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Método de produção de derivados de hidroxialquil amido
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
AU2003273413A1 (en) * 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US20040072729A1 (en) * 2002-10-10 2004-04-15 Sunbio Inc. High oxygen affinity PEG-hemoglobin as treatment for brain stroke
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
NZ542094A (en) 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
JP2004307404A (ja) 2003-04-08 2004-11-04 Nipro Corp 人工酸素運搬体を含む医薬組成物
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1613261A4 (en) * 2003-04-09 2011-01-26 Novo Nordisk As INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20080146782A1 (en) 2006-10-04 2008-06-19 Neose Technologies, Inc. Glycerol linked pegylated sugars and glycopeptides
BRPI0410164A (pt) 2003-05-09 2006-05-16 Neose Technologies Inc composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
EP1653991A2 (en) * 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Conjugates of a polymer and a protein linked by an oxime linking group
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
SG145746A1 (en) * 2003-08-08 2008-09-29 Fresenius Kabi De Gmbh Conjugates of hydroxyalkyl starch and g-csf
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
EP1694347B1 (en) * 2003-11-24 2013-11-20 BioGeneriX AG Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7521174B2 (en) * 2003-12-05 2009-04-21 Albert Einstein College Of Medicine Of Yeshiva University Universal red blood cells, methods of preparing same, and uses thereof
WO2005070138A2 (en) 2004-01-08 2005-08-04 Neose Technologies, Inc. O-linked glycosylation of peptides
ES2720078T3 (es) 2004-01-21 2019-07-17 Nektar Therapeutics Método para preparar polímeros terminados en ácido propiónico
SG135176A1 (en) 2004-02-02 2007-09-28 Ambrx Inc Modified human four helical bundle polypeptides and their uses
EA010501B1 (ru) 2004-03-11 2008-10-30 Фрезениус Каби Дойчланд Гмбх Конъюгаты гидроксиалкилкрахмала и белка, полученные восстановительным аминированием
WO2005092369A2 (en) * 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyethyl starch and erythropoietin
CN101080246A (zh) 2004-04-28 2007-11-28 安希奥设备国际有限责任公司 用于形成交联生物材料的组合物和系统及关联的制备方法与用途
ES2339953T5 (es) 2004-05-04 2020-05-06 Novo Nordisk Healthcare Ag Glicoformas de factor VII ligadas a O y método de fabricación
CN102603895B (zh) 2004-06-18 2016-09-28 Ambrx公司 新颖抗原结合多肽和其用途
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP1789437A4 (en) * 2004-07-30 2008-11-05 Sinai School Medicine INHIBITORS OF NPC1L1 AND NPC1L1 AND METHODS OF USE THEREOF
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
EP1796602A4 (en) 2004-09-17 2016-10-19 Angiotech Pharm Inc MULTIFUNCTIONAL COMPOUNDS FOR PRODUCING NETWORKED BIOMATERIALS AND MANUFACTURING AND USE METHOD THEREFOR
JP2008514215A (ja) * 2004-09-29 2008-05-08 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 改変タンパク質
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
MX2007007581A (es) 2004-12-22 2007-07-24 Ambrx Inc Composiciones de amino acil-arnt sintetasa y sus usos.
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
WO2006073846A2 (en) 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
CN103690936A (zh) 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
US20100062973A1 (en) * 2005-03-11 2010-03-11 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material
US20060246544A1 (en) * 2005-03-30 2006-11-02 Neose Technologies,Inc. Manufacturing process for the production of peptides grown in insect cell lines
US20070154992A1 (en) * 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
CN101247821B (zh) * 2005-06-03 2013-01-23 Ambrx公司 经改良人类干扰素分子和其用途
JP4829969B2 (ja) * 2005-08-18 2011-12-07 アンブルックス，インコーポレイテッド ｔＲＮＡ組成物、およびその使用
CA2619969A1 (en) * 2005-08-19 2007-02-22 Neose Technologies, Inc. Glycopegylated factor vii and factor viia
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
HRP20110404T1 (hr) * 2005-11-08 2011-08-31 Ambrx Ubrzivači za modifikaciju ne-prirodnih aminokiselina i polipeptida ne-prirodnih aminokiselina
KR20080079643A (ko) * 2005-11-16 2008-09-01 암브룩스, 인코포레이티드 비-천연 아미노산을 포함하는 방법 및 조성물
AU2006326404B2 (en) * 2005-12-14 2011-11-03 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
US20080248959A1 (en) * 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
CA2663083A1 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
CN101541955B (zh) * 2006-09-08 2016-09-28 Ambrx公司 用于脊椎动物细胞的杂合抑制tRNA
EP2064333B1 (en) * 2006-09-08 2014-02-26 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
MX2009011870A (es) * 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
EP2170919B8 (en) 2007-06-12 2016-01-20 ratiopharm GmbH Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
NZ620606A (en) 2008-02-08 2015-08-28 Ambrx Inc Modified leptin polypeptides and their uses
EP2626079A3 (en) 2008-02-27 2014-03-05 Novo Nordisk A/S Conjungated factor VIII molecules
PE20110426A1 (es) 2008-07-23 2011-07-01 Ambrx Inc Polipeptidos g-csf bovinos modificados
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
PT2337846T (pt) 2008-09-26 2018-04-05 Ambrx Inc Vacinas e microrganismos dependentes da replicação de aminoácidos não naturais
NZ597022A (en) 2009-06-09 2014-05-30 Prolong Pharmaceuticals Llc Hemoglobin compositions
US8273857B2 (en) * 2009-09-22 2012-09-25 Jen-Chang Hsia Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine
JP2013515080A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用
WO2011087810A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US9493616B2 (en) 2010-02-25 2016-11-15 Sangart, Inc. Methods for preparing PEG-hemoglobin conjugates using reduced reactant ratios
AU2011291943B2 (en) 2010-08-17 2015-01-22 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
BR112015004022B1 (pt) 2012-08-31 2023-04-25 Sutro Biopharma, Inc Aminoácidos modificados compreendendo um grupo azido
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
SG11201702824UA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
US20180223479A1 (en) * 2017-02-07 2018-08-09 Rayonier Performance Fibers, Llc Dual function reagent, transfer fibers, transfer layer, and absorbent articles
KR102670432B1 (ko) 2017-02-08 2024-05-28 브리스톨-마이어스 스큅 컴퍼니 약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
US10415189B2 (en) * 2017-10-03 2019-09-17 Rayonier Performance Fibers, Llc Polyalkylene glycol based reagent with aldehyde end groups suitable for making cellulosic fibers with modified morphology
SG11202102427XA (en) 2018-09-11 2021-04-29 Ambrx Inc Interleukin-2 polypeptide conjugates and their uses
CA3174114A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612308A (en) * 1979-07-11 1981-02-06 Ajinomoto Co Inc Blood substitute

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136093A (en) * 1976-04-23 1979-01-23 Biotest-Serum-Institut Gmbh Hemoglobin preparation with increased oxygen release

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612308A (en) * 1979-07-11 1981-02-06 Ajinomoto Co Inc Blood substitute

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5989629A (ja) * 1982-11-15 1984-05-23 Ajinomoto Co Inc 代用血液
JPS6153223A (ja) * 1984-08-22 1986-03-17 Ajinomoto Co Inc ヘモグロビン−ポリアルキレングリコ−ル結合体の製造方法
JPS6289630A (ja) * 1985-06-19 1987-04-24 Ajinomoto Co Inc ヘモグロビン―ポリオキシアルキレン結合体
JPH01500524A (ja) * 1986-07-02 1989-02-23 パスツール・メリュー・セルム・エ・バクサン ヘモグロビン高分子複合体、その調製方法及びその利用分野
JP2005515225A (ja) * 2002-01-11 2005-05-26 サンガート， インコーポレイテッド 高酸素親和性改変ヘモグロビンを含む、酸素輸送のための方法および組成物
JP2010138197A (ja) * 2002-01-11 2010-06-24 Sangart Inc 高酸素親和性改変ヘモグロビンを含む、酸素輸送のための方法および組成物
US7235639B2 (en) 2003-04-23 2007-06-26 Ezio Panzeri Hemoglobin conjugates

Also Published As

Publication number Publication date
EP0067029B1 (en) 1986-04-30
EP0067029A2 (en) 1982-12-15
DE3270842D1 (en) 1986-06-05
US4412989A (en) 1983-11-01
EP0067029A3 (en) 1983-08-03
JPH026337B2 (enExample) 1990-02-08

Similar Documents

Publication Publication Date Title
JPS57206622A (en) Blood substitute
ATE57614T1 (de) Ibuprofen enthaltende weichgelatinekapseln und verfahren zu ihrer herstellung.
SE8601135D0 (sv) Kemiskt modifierat hyaluronsyrapreparat och metod for utvinning derav ur djurvevnader
JPS57194787A (en) Culture medium for animal cell
JPS53113008A (en) Constant rate releasing preparation
JPS54109983A (en) Novel spiroamine derivative and its preparation
JPS5670028A (en) Polymer bonding with albumin
DE3669041D1 (de) Pyridopyrimidine, mehrere verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
DE59009449D1 (de) Verfahren zur herstellung von äthercarbonsäuren aus kohlenhydraten und deren derivaten.
DE3574935D1 (de) Loesungen fuer die peritonealdialyse.
JPS57156479A (en) Ascorbic acid derivative
JPS6460375A (en) Chemical modification of bilirubin oxidase
IL65936A (en) Chloroacetic acid cyclohexylamides,their preparation and their use as herbicides
JPS5489987A (en) Arsenic capturing material
KR920006008A (ko) 골(骨) 형성 촉진 물질의 제조법
JPS5378665A (en) Method of refining valuable substance contained liquid
JPS5759627A (en) Solubilization
JPS5639055A (en) S-polyprenylpeptides
JPS5387400A (en) Collection of protein
JPS5432597A (en) Purification of high molecular weight alkylene oxide polymer
ATE18410T1 (de) Kristallines human-leukocyten-interferon.
JPS53127808A (en) Preparation of human albumin
JPS5655398A (en) Purification of glycyrrhizin
JPS5626526A (en) Selective permeable membrane for separation of gas
JPS5520717A (en) Saccharide-transfusing agent